CNJ.TO  Cangene Cp

Exchange

TSX

Sector

Life Sciences

Industry

Market Cap.

240.3M

Vuru Grade

37.31/100

Current Price

$3.60
0.00 (0.00%)

Growth Price

$4.52
Undervalued by 25.65%

Stability Price

$2.17
Overvalued by 39.67%

Company Metrics

  • P/E 169
  • P/S 2.08
  • P/B 1.25
  • EPS -0.15
  • Cash ROIC 5.13%
  • Cash Ratio 1.47
  • Dividend 0 / 0%
  • Avg. Vol. 255,197.00
  • Shares 66.75M
  • Market Cap. 240.3M

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire (press release) - Feb 21, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects ...
Cangene Announces Completion of Acquisition by Emergent BioSolutions - Canada NewsWire (press release)
Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.
Washington Post - Dec 12, 2013
Emergent BioSolutions established itself as a leading biodefense company by selling Anthrax vaccines en masse to the federal government in the wake of Sept.
Cangene bought by US rival for $236-million, latest Canadian biotech taken private - The Globe and Mail
Emergent BioSolutions expanding with $222M deal to buy Cangene - FiercePharma
Cangene To Be Acquired By Emergent BioSolutions For US$222 Million
Canada NewsWire (press release) - Dec 11, 2013
11, 2013 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE: EBS) of Rockville, Maryland will acquire Cangene in an all-cash transaction ...
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene
News-Medical.net - Feb 20, 2013
Inspiration Biopharmaceuticals (Inspiration) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene). The transaction ...
Pernix Therapeutics (PTX) Stock: Climbing Dramatically On Acquisition Rumor
CNA Finance (press release) - Aug 19, 2016
... to mergers and acquisitions. It is not uncommon for Sedor to take a CEO position, restructure the company to make sure that they are primed for an acquisition, and strike on making a deal.
Cangene takeover might not be a bad thing
Winnipeg Free Press - Dec 20, 2013
The recently announced proposed sale of Cangene Corp. to Emergent BioSolutions Inc. of Maryland for $222 million is bringing up those concerns once again.
CANGENE bioPHARMA FACILITY RENOVATION IS COMPLETE AND OPERATING AT EXPANDED ...
PR Newswire (press release) - May 2, 2011
BALTIMORE AND WINNIPEG, May 2 /PRNewswire/ - Cangene Corporation's Baltimore-based injectable pharmaceutical contract-manufacturing subsidiary, Cangene bioPharma, Inc., has completed a US$11-million renovation of its sterile filling and support ...
FDA approves treatment for inhalation anthrax
FDA.gov - Mar 25, 2015
The product is manufactured by Cangene Corporation, based in Winnipeg, Canada. It was developed with support from BARDA within HHS' Office of the Assistant Secretary for Preparedness and Response.
FDA Approves Anthrasil For Anthrax Treatment - Tech Times
WinRho SDF for ITP: Cangene announces new safety information
News-Medical.net - Mar 26, 2010
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho(R) SDF (Rho (D) Immune Globulin (Human)) for the treatment of ...
Cangene Appoints New Chief Financial Officer
Canada NewsWire (press release) - Jun 15, 2012
WINNIPEG, June 15, 2012 /CNW/ - Cangene Corporation, a biopharmaceutical company primarily focused on hospital based therapeutics, today announces that it has appointed Mr. Jeff Lamothe as its new Chief Financial Officer, to be effective August 1, ...